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Primitive erythropoiesis defines the onset of hemato-
poiesis in the yolk sac of the early embryo and is
initiated by the emergence of progenitors assayed
as colony-forming cells (EryP-CFCs). EryP-CFCs
are detected for only a narrowwindow during embry-
onic development, suggesting that both their initia-
tion and termination are tightly controlled. Using
the embryonic stem differentiation system to model
primitive erythropoiesis, we found that miR-126
regulates the termination of EryP-CFC development.
Analyses of miR-126 null embryos revealed that
this miR also regulates EryP-CFCs in vivo. We identi-
fied vascular cell adhesion molecule-1 (Vcam-1) ex-
pressed by a mesenchymal cell population as a
relevant target of miR-126. Interaction of EryP-
CFCs with Vcam-1 accelerated their maturation to
ßh1-globin+ and Ter119+ cells through a Src family
kinase. These findings uncover a cell nonautono-
mous regulatory pathway for primitive erythropoiesis
that may provide insight into the mechanism(s)
controlling the developmental switch from primitive
to definitive hematopoiesis.
INTRODUCTION
The onset of hematopoiesis in the yolk sac of the mouse
embryo is characterized by the emergence of blood islands
that are comprised of clusters of primitive erythroblasts
surrounded by developing vascular cells (reviewed by Ferko-
wicz and Yoder, 2005). Primitive erythropoiesis represents
a unique hematopoietic program in that its emergence is
restricted to the yolk sac, and the progenitors assayed as
colony-forming cells (EryP-CFCs) are present only during a
defined temporal window early in mouse development (Palis
et al., 1999). Studies using model organisms and the mouse
embryonic stem cell (ESC) differentiation system have providedDstrong evidence that the primitive erythroid lineage derives from
a Flk-1+ mesodermal progenitor known as the hemangioblast
(Choi et al., 1998; Huber et al., 2004; Nishikawa et al., 1998).
The hemangioblast develops prior to the onset of primitive
erythropoiesis and displays the capacity to generate both
hematopoietic (including primitive erythroid) and vascular
progeny (Choi et al., 1998). As observed in the yolk sac, prim-
itive erythropoiesis in the mESC system represents a transient
program that emerges following the development of the he-
mangioblast and persists for a defined period of time (Nostro
et al., 2008; Palis et al., 1999). The striking similarities between
yolk sac- and mESC-derived primitive erythropoiesis strongly
support the notion that this in vitro model faithfully recapitulates
hematopoietic development and, as such, provides a tractable
system for investigating the regulation of this early blood cell
program.
The temporal nature of primitive erythropoiesis points to tight
controls regulating both the onset and the cessation of EryP-
CFC production. Studies using the mESC model have provided
important insights into signaling pathways that regulate the
establishment of the lineage, including the induction of hemato-
poietic mesoderm and its specification to the primitive erythroid
lineage. Findings from these studies have shown that BMP is
essential for induction of Flk-1+ mesoderm, whereas VEGF/
Flk-1 signaling is required for specification of the mesoderm to
the hematopoietic fates (Choi et al., 1998; Nostro et al., 2008;
Pearson et al., 2008). Following hematopoietic specification,
the primitive erythroid lineage is established through coordi-
nated activation of the canonical Wnt pathway and inhibition of
Notch signaling (Cheng et al., 2008). While these data provide
a framework for the network of pathways that control the onset
of primitive erythropoiesis, the termination of EryP-CFC develop-
ment is poorly understood.
One class of regulators that could be involved in temporal
regulation of primitive erythroid progenitor development is
microRNAs, which function to silence genes by either transla-
tional repression or mRNA degradation (Bartel, 2004). To date,
over 600 mouse microRNAs are annotated within the miRBase
database (Griffiths-Jones, 2004), highlighting the potential of
these molecules to regulate multiple stages of development
and cell function across many cell lineages. Due to theirevelopmental Cell 23, 45–57, July 17, 2012 ª2012 Elsevier Inc. 45
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RNAs represent an ideal mechanism for controlling critical devel-
opmental stages in the embryo that involve the rapid induction
and specification of distinct cell types in close proximity
(reviewed in Kloosterman and Plasterk, 2006). An essential role
formicroRNAs in early development is demonstrated by the early
lethality of embryos lacking Dicer, a nuclease essential for micro-
RNA biogenesis (Bernstein et al., 2003). MicroRNAs have been
shown to play multiple roles in the specification and function of
different cell types, including those of the hematopoietic, cardio-
vascular, and neuronal systems (reviewed in Ivey and Srivastava,
2010).
In this study, we used mESC-derived cell populations to
screen for potential microRNA(s) that could play a role in
early hematopoietic development and identified miR-126 as
a regulator of the primitive erythroid lineage. We found that
inducible overexpression of miR-126 prolongs the duration of
EryP-CFC development in the mESC model, whereas its tar-
geted deletion has the opposite effect. miR-126 exerts these
effects through the repression of Vascular cell adhesion mole-
cule-1 (Vcam-1) in a nonhematopoietic mesenchymal popula-
tion. Vcam-1 regulates primitive erythropoiesis by accelerating
maturation of primitive erythroblasts toward ßh1-globin ex-
pressing, Ter119+ erythroid cells, via a Src-family kinase
(SFK). Collectively, these findings define a cell nonautonomous
regulatory pathway for primitive erythropoiesis involving miR-
126, Vcam-1 and SFK.
RESULTS
miR-126 Is Expressed in a Yolk-Sac-like Population
To identify microRNAs that could play a role in early hematopoi-
etic development, we performed microarray analysis to assess
microRNA expression in mESC-derived populations represent-
ing distinct developmental stages in the pathway from the
mESC to blood. Populations used for these analyses included
epiblast-like cells prior to induction of a primitive streak (PS) pop-
ulation, Brachyury+ and Brachyury+Foxa2+ cells representing
a PS-like cell population, and cardiac and hematopoietic meso-
derm generated from the PS cells. (Figure S1A available online).
This screen identified microRNAs that were preferentially ex-
pressed at different stages of the developmental scheme
including miR-302a and the miR-291–295 cluster in the PS-like
population and miR-1 in cardiac mesoderm, consistent with
published findings (Zhao et al., 2005; Figure S1B). miR-126-3p
displayed an interesting pattern as its expression was upregu-
lated with commitment to the hematopoietic and cardiac lineage
(Figures S1B and S1C). Previous studies have shown that miR-
126-3p is expressed in both vascular cells and hematopoietic
progenitors (Donahue et al., 2009; Garzon et al., 2006; Gentner
et al., 2010; Grabher et al., 2010; Harris et al., 2008, 2010; Jin
et al., 2008; Kuehbacher et al., 2007; Lagos-Quintana et al.,
2002; Landgraf et al., 2007; Li et al., 2008; Nicoli et al., 2010;
O’Connell et al., 2010; Poliseno et al., 2006; Shen et al., 2008;
Wienholds et al., 2005; Yang et al., 2009) and that it plays
a role in vasculogenesis/vascular integrity (Fish et al., 2008;
Wang et al., 2008). Given this expression pattern, we chose to
further investigate the role of miR-126-3p in early hematopoietic
development.46 Developmental Cell 23, 45–57, July 17, 2012 ª2012 Elsevier Inc.miR-126 Is Expressed in a VEGF-Dependent Manner in
a Population Containing Primitive Erythroid Progenitors
Given the coincident upregulation of miR-126 with hematopoi-
etic commitment, we were interested in determining if its expres-
sion was induced by one of the regulators of this developmental
program. To address this, we generated a mESC reporter line
containing a sensor to enable us to rapidly monitor miR-126
expression. A constitutively expressed tdRFP reporter contain-
ing two complementary binding sites to miR-126-3p in its
30UTR (Luche et al., 2007; Mansfield et al., 2004) was inserted
within the ROSA26 locus (Figure 1Ai). Factors known to regulate
the differentiation of mESCs to mesoderm (Gadue et al., 2006;
Nostro et al., 2008; Pearson et al., 2008) were added to differ-
entiation cultures, and tdRFP fluorescence was monitored
temporally by flow cytometry (Figure 1Aii). None of the PS
inducers, including Wnt3a, Activin A, or BMP4, reduced tdRFP
fluorescence (Figure 1Aiii), indicating that they did not induce
expression of miR-126. In contrast, addition of VEGF resulted
in a loss of tdRFP beginning at day 5 of differentiation, demon-
strating that signaling through the Flk-1 receptor induces func-
tional miR-126-3p expression (Figure 1Aiii).
Titration of VEGF showed that induction of miR-126-3p (loss
of tdRFP) and hematopoietic specification as measured by
upregulation of CD41 expression are coordinated and require
similar levels of signaling (Figure 1B). Kinetic analyses of
mESC-derived populations induced with Wnt3a, BMP4, Activin
A, and VEGF in serum-free conditions revealed a defined
temporal pattern of primitive erythropoiesis, with EryP-CFCs
emerging at day 4 of differentiation, peaking in number at day
5 and showing a rapid decline by day 6 (Figure 1C; Nakano
et al., 1996; Nostro et al., 2008; Palis et al., 1999). Expression
of miR-126-3p and its host gene, Egfl7, were upregulated
with the onset of primitive erythropoiesis at day 4 of differ-
entiation and maintained for the duration of the timecourse
(Figures 1D, S2A, and S2B, black bars). To determine if expres-
sion of miR-126-3p changed as the primitive erythroid lineage
matured, EryP-CFCs were cultured under serum-free condi-
tions known to support their maturation and assayed and
analyzed at daily intervals. Within 24 hr of erythropoietin (EPO)
exposure in methylcellulose, miR-126-3p, and Egfl7 expression
dropped significantly and remained low throughout the 5 days
of culture (Figures 1E and S2I), indicating that expression is
not maintained during maturation of the primitive erythroid
lineage.
Enforced miR-126 Expression in Differentiating EBs
Alters Primitive Erythropoiesis through a Flk-1+
Progenitor
To investigate a potential role for miR-126 in hematopoietic
development, we engineered the AINV mESC line to allow tet-
inducible miR-126 expression (Figure 2A; Kyba et al., 2002).
With this line, expression of the gene of interest can be induced
at any stage of differentiation by the addition of doxycycline
(DOX) to the culture. Induction at early stages of differentiation
(days 0–4) prior to endogenous expression of miR-126 resulted
in a substantial decrease in total EB cell number and poor differ-
entiation (data not shown). Overexpression in the methylcellu-
lose EryP-CFC assay was also inhibitory and resulted in poor
colony growth (Figure S2J), consistent with the downregulation
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Figure 1. Induction of Expression of miR-126-3p
(A) Scheme showing the mESC line carrying a targeted miR-126-3p endogenous expression sensor. (i) tdRFPwith two complimentary miR-126-3p sequences in
the 30UTR was placed under control of the ROSA26 promoter. (ii) Differentiation schematic for monitoring endogenous miR-126-3p expression. Differentiated
mESCs were reaggregated after 48 hr and further differentiated in the presence of indicated factors. Induced populations were assayed via flow cytometry for
tdRFP fluorescence every 24 hr for 96 hr. Day 3, red; day 4, blue; day 5, green; day 6, orange.
(B) EndogenousmiR-126-3p expression correlates with hematopoietic surfacemarker expression. Increasing concentrations of VEGFwere added to sorted D3.5
Flk-1+ cells, and CD41 expression was monitored alongside tdRFP via flow cytometry 48 hr later.
(C and D) Kinetics of EryP-CFC development (C) and miR-126-3p expression in EBs (D).
(E) miR-126-3p is expressed in the EryP-CFC progenitor pool, but not maturing erythroblasts. EryP-CFC containing cells from day 5 of differentiation (C) were
plated in methylcellulose, harvested every 24 hr as primitive erythroid colonies emerge, and quantified for miR-126-3p expression. nR 3 (mean ± SD).
See also Figure S1.
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observations highlight the importance ofmanipulatingmicroRNA
expression levels at appropriate stages in developmental
models.
Addition of DOX to differentiating EBs at day 4 of culture
(Figure 2A) resulted in a 4-fold increase in miR-126-3p expres-
sion by day 6 (Figure S2A). Induction of miR-126 did not alter
Egfl7 expression (Figure S2B) nor did it affect cell proliferation,
because total cell numbers in the induced and noninduced
EBs were the same (Figure S2C). miR-126 overexpression did
result in a striking 4-fold increase in the frequency and total
number of EryP-CFCs detected in day 6 EBs (Figures S2D
and 2B). Interestingly, this increase was not observed at day 5,
suggesting that the effect is restricted to the termination of
the primitive progenitor development. Regardless of miR-126
expression levels, however, the effect on primitive erythropoiesisDdid not persist to day 7 of differentiation as only low numbers
of EryP-CFC were detected in all cultures (data not shown).
To determine if a loss of miR-126-3p would have an opposite
effect on EryP-CFC development, we generated a miR-126/
mESC line by targeting the second allele in the miR-126+/
heterozygous cell line (Wang et al., 2008). Analyses of these
EBs showed that miR-126-3p was not detectable at any
stage of differentiation (Figure S2A0), whereas Egfl7 expression
was slightly elevated (Figure S2B0). Cellular proliferation was
unchanged between miR-126/ and miR-126+/ EBs (Fig-
ure S2C0). Loss of miR-126 significantly impacted primitive
erythropoiesis as day 6 EBs generated from themiR-126/ cells
showed more than a 2-fold reduction in total EryP-CFCs
compared to miR-126+/-derived EBs (Figures 2C and S2D0).
Myeloid progenitor numbers were not reduced in the miR-
126/ EBs (Figure S2E), demonstrating that the effect isevelopmental Cell 23, 45–57, July 17, 2012 ª2012 Elsevier Inc. 47
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Figure 2. Manipulation of miR-126 Expression Alters Flk-1-Derived Primitive Erythroid Potential
(A) Differentiation scheme for monitoring EryP-CFCs potential following induction of miR-126 expression. Doxycycline (DOX; 2 mg/ml) was added to the EBs at
day 4 of culture. EBs harvested on the day of DOX addition, or 24 and 48 hr later, were dissociated by trypsinization and the cells were plated inmethylcellulose for
EryP-CFC analysis.
(B) Total numbers of EryP-CFCs in induced and noninduced cultures.
(C) Total numbers of EryP-CFCs in cultures generated from miR-126+/ and miR-126/ mESCs.
(D) Differentiation scheme outlining the strategy for the generation, isolation, and differentiation of the Flk-1+ progenitor population.
(E and F) Total number of EryP-CFCs in Flk-1+-derived aggregates cultured for 2 days (48 hr) or 3 days (72 hr) following addition of DOX, and (F) total number of
primitive erythroblasts generated from the EryP-CFCs in (E).
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Primitive Erythropoiesis Is Regulated by miR-126restricted to the primitive erythroid lineage. As with the enforced
expression studies, the effect was only observed at day 6 of
differentiation, further supporting the interpretation that miR-
126 does not play a role in the initiation of primitive erythropoi-
esis, but rather is involved in the termination of EryP-CFC
production.
The observation that VEGF controls miR-126 expression
suggests that the effect on primitive erythropoiesis may be
mediated via a Flk-1+ progenitor, possibly through derivative
hematopoietic, endothelial, or vascular cell-types (Choi et al.,
1998; Kennedy et al., 1997). To investigate this possibility, we
isolated the Flk-1+ (hemangioblast) population from day 3.0–
3.5 Wnt3a/Activin/BMP4 induced EBs, aggregated the cells
in the presence of VEGF, and cultured the aggregates for an
additional 3 days (Figure 2D). As with the whole EB population,
VEGF induced miR-126-3p and Egfl7 expression in a dose-
dependent fashion (Figure S2F) and the expression was main-
tained for at least 72 hr (Figure S2G).
Peak numbers of EryP-CFCs were detected within 48 hr of
culture after which time they declined sharply, indicating that
these progenitors display a temporal pattern of development in
the Flk-1+-derived aggregates, similar to that observed in whole
EBs. As expected from our previous study (Nostro et al., 2008),
addition ofWnt3a to the aggregate cultures increased progenitor
numbers at both time points but did not significantly alter
the overall pattern of development (Figure 2E). Enforced overex-
pression of miR-126 at the onset of culture (day 3.0) did not
affect proliferation of Flk-1+ cells or hemangioblast potential of
the population as measured by blast colony-forming cells (Fig-
ure S2H). miR-126 expression was also unable to induce primi-
tive erythropoiesis in the absence of VEGF (data not shown).
Induced expression did, however, result in 3.3- and 2.1-fold
increases in the total EryP-CFC number at 72 hr in the VEGF-
and VEGF+Wnt3a-stimulated cultures, respectively (Figure 2E).
Furthermore, colonies generated from the induced populations
were approximately 2-fold larger in size compared to those
that developed from the noninduced progenitors (not shown),
translating to a 6- and 4-fold increase in total numbers of primi-
tive erythroblasts generated in the VEGF- or VEGF+Wnt3a-
stimulated cultures (Figure 2F). As expected from the whole EB
studies, miR-126/ Flk-1+ aggregates stimulated with VEGF
and Wnt3a for 72 hr generated significantly fewer EryP-CFCs
(43%) and total primitive erythroblasts (50%) compared to the
miR-126+/ Flk-1+ cells (Figures 2G and 2H).
To determine if miR-126 regulates primitive erythropoiesis
in vivo, we next analyzed the yolk sacs from miR-126 null
embryos (Wang et al., 2008) for EryP-CFCs. As observed with
the miR-126/ EBs, yolk sacs from miR-126/ embryos con-
tained significantly fewer EryP-CFCs than yolk sacs from the
miR-126+/ embryos (Figure 2I; Table S1). Similar numbers of
EryP-CFCs were detected in the miR-126+/ and miR-126+/+
yolk sacs.
Collectively, these findings provide strong evidence that
miR-126 plays a regulatory role in the termination of primitive(G) Total number of EryP-CFC generated in miR-126+/ and miR-126/ Flk-1+-d
(H) Total number of primitive erythroblasts generated from the EryP-CFCs in (G;
(I) In vivo yolk sac EryP-CFC potential from miR-126+/+, miR-126+/, and miR-126
See also Figure S2 and Table S1.
Derythropoiesis and that this effect is mediated within the Flk-1+
hemangioblast-derived population.
miR-126-3p Regulates Vcam-1 Expression on
Nonhematopoietic Cells, Which Regulate EryP-CFC
Potential
In the tet-inducible and targeted cell lines, both miR-126-3p
and miR-126-5p are experimentally modulated (Figure S3A).
Therefore, in order to define the targets regulated by miR-126
that could be responsible for the effects on the primitive
erythroid lineage, we chemically modulated miR-126-5p or -3p
expression independently using antagomirs (Kru¨tzfeldt et al.,
2005). Inhibition of miR-126-3p, but not miR-126-5p, resulted
in a 40% reduction of EryP-CFC in reaggregated Flk-1+ cells
(Figure S3B), indicating that miR-126-3p, and not -5p, is respon-
sible for the observed regulatory effects on the primitive
erythroid program.
qRT-PCR analysis of recently published targets of miR-
126-3p, including Ptpn9, Spred1, and Pi3kr2, excluded them
as potential targets for the primitive erythroid effect as their
expression patterns in different aged EBs were not influenced
by the absence of miR-126-3p or by its enforced expression
(Figures S3C and S3D and data not shown). Vcam-1, on the
other hand, was identified as a candidate target in the day 6
EB population (Harris et al., 2008). Kinetic analysis of whole
EBs revealed that Vcam-1 expression levels increased signifi-
cantly between days 5 and 6 of differentiation, coincident with
the decline in primitive erythropoiesis observed at the end
of the program (Figure 3A). Expression levels at day 6 were
reduced (37%) in DOX-induced day 6 EBs compared to non-
treated control EBs, whereas they were 2.3-fold higher in miR-
126/ EBs than in miR-126+/ EBs (Figures 3A and 3B). These
changes were also observed at the protein level as DOX-treated
day 6 EBs contained fewer Vcam-1high cells than noninduced
EBs, whereas the miR-126/ EBs had a larger Vcam-1high pop-
ulation than the corresponding miR-126+/ EBs (Figure 3C).
To determine if Vcam-1(CD106) is a regulator of primitive
erythropoiesis, we antagonized its expression through inducible
expression of a shRNA against Vcam-1 using the tet-inducible
AINV mESC line. Screening for functional shRNA against
Vcam-1 indentified 1 clone wherein stably-transfected mESC
were differentiated and assayed for primitive erythropoiesis as
in Figure 2A. shRNA against Vcam-1 decreased Vcam-1 expres-
sion by 25% (Figure S3E) and increased total EryP-CFCs by
2-fold (Figure S3F). DOX induction of the same Vcam-1 shRNA
at day 4 of differentiation resulted in a 2.3-fold reduction in the
size of Vcam-1high population (Figure 3D) and a comparable
(2.3-fold) increase in the total number of EryP-CFCs at day 6 of
differentiation (Figure 3E). Similarly, DOX induction in day 3.0
Flk-1+-derived aggregates decreased Vcam-1 expression (Fig-
ure S3G) and resulted in 3.3- and 2.3-fold increases in total
EryP-CFCs in VEGF- and VEGF+Wnt3A-induced reaggregates
(Figure S3H). The increase in total primitive erythroblasts was
4.5-fold and 2.1-fold for the VEGF- and VEGF+Wnt3a-treatederived aggregates at 72 hr of culture.
mean ± SD).
/ embryos (mean ± SEM). nR 3. Student’s paired t test *p < 0.05, **p < 0.01.
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Figure 3. miR-126 Regulates Vcam-1 Expression, Which Negatively Regulates EryP-CFC Development
(A–D) qRT-PCR based expression analyses of Vcam-1 in miR-126 overexpression (A) andmiR-126/ (B) EBs, as in Figure 2A. Flow cytometric analyses showing
the percent of Vcam-1+ cells in (C) nonmanipulated, miR-126 induced, miR-126/ and miR-126+/ EBs at the indicated days of differentiation, and (D) in EBs
following expression of a tet-inducible anti-Vcam-1 shRNA.
(E) Total number of EryP-CFCs in Vcam-1 shRNA overexpression EBs.
(F and G) qRT-PCR analysis of Vcam-1 (F) and miR-126 (G) in wild-type yolk sacs. nR 3. (mean ± SD) Student’s paired t test *p < 0.05, **p < 0.01.
See also Figure S3.
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Primitive Erythropoiesis Is Regulated by miR-126reaggregates, respectively (Figure S3I). No changes in cell
growth were observed (data not shown). The strikingly similar
outcomes of manipulating either miR-126 or Vcam-1 indicate50 Developmental Cell 23, 45–57, July 17, 2012 ª2012 Elsevier Inc.that Vcam-1 is not only a relevant target of miR-126-3p, but
it also plays a pivotal role in the regulation of primitive
erythropoiesis.
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Figure 4. Vcam-1+ Cells Are a Transient
Lineage with Mesenchymal Characteristics
(A) Vcam-1 is not expressed on hematopoietic
(CD41) or endothelial (CD31) cells in either differ-
entiating EBs (top row) or 4-6 somite yolk sacs
(bottom row).
(B) Morphology of FACS-purified mESC-derived
Vcam-1+ cells (1003).
(C) Sorted mESC-derived Vcam-1+ cells cultured
on gelatin prior to differentiation exhibit low
expression of the MSC markers CD73 and CD105
but lack CD90 (blue lines).
(D) Mesenchymal differentiation of mESC-derived
Vcam-1+ cells toward chondrocytes (i; alcian blue
staining), adipocytes (ii; oil red o staining), and
osteocytes (iii; alizarin red staining).
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Primitive Erythropoiesis Is Regulated by miR-126In the developing mouse embryo, Vcam-1 has been found in
both the allantois and mesenchyme of the early yolk sac (Downs
et al., 2004; Gurtner et al., 1995; Kwee et al., 1995; Sheppard
et al., 1994). Analyses of yolk sacs (minus allantois) from different
aged embryos revealed a steady increase in Vcam-1 expression
from E7.0 to the 7-9 somite pair (sp) stage. The levels dropped
sharply between the 7-9 and 10-14 sp stages, a pattern indica-
tive of rapid inhibition of expression (Figure 3F). miR-126-3p
expression increased modestly until the 7-9 sp stage and then
dramatically at the 10-14 sp stage, coincident with the decline
in Vcam-1 expression (Figure 3G). Interestingly, these dynamic
changes in miR-126 and Vcam-1 expression occur during the
simultaneous loss of adhesion molecules on EryP-CFCs, the
termination of their development, and the rapid vasculature re-
modeling that occurs in the yolk sac at the onset of circulation
(reviewed in Baron et al., 2012; Palis et al., 2010).
Flow cytometric analyses of whole EBs and mouse yolk sacs
showed that the Vcam-1 population does not express CD41 or
CD31 (Figure 4A), indicating that these cells are neither hemato-
poietic nor endothelial. When isolated from day 6 EBs and
cultured on gelatin-coated dishes for 48 hr, the Vcam-1+ cells
formed a monolayer that displayed a mesenchymal/fibroblastic
morphology (Figure 4B). Analyses of surface markers typically
found on mesenchymal cells revealed that, upon sorting and
culture in serum, these cells express PDGFRa (Figure 4A) and
low levels of CD73. Approximately 20% of the cells acquireDevelopmental Cell 23, 4CD105+, but none express CD90 (Fig-
ure 4C). When assayed under appropriate
conditions, the Vcam-1+ cells displayed
multi-potent mesenchymal-lineage differ-
entiation capacity, undergoing chondro-
genesis, adipogenesis, and osteogenesis
(Figure 4D). Taken together, these data
demonstrate that the Vcam-1+ cells
represent an embryonic mesenchymal
cell population that differs from most
other mesenchymal cells with respect to
expression patterns of surface markers.
To determine if the Vcam-1+-derived
population could impact primitive ery-
throid development in vitro, day 4 EBs
containing EryP-CFCs were dissociated,and the cells were cultured on Vcam-1-derived monolayers
(Figure 5A). EryP-CFCs were also cocultured with EB-derived
CD31+ monolayers as a control. Following 48 hr of culture, the
cells were harvested and assayed for EryP-CFC potential. Pop-
ulations cultured on the Vcam-1+ cells showed a sharp reduction
in EryP-CFC potential compared to cells cultured on the CD31+
monolayer or on gelatin alone (Figure 5B), further supporting the
interpretation that the Vcam-1+ population negatively regulates
primitive erythroid development in the EBs.
Vcam-1-Mediated Repression of EryP-CFC Potential
Molecular analyses revealed that the Vcam-1+ cells express the
Notch agonist Jag-1 and the canonical Wnt antagonist Dkk-1
(Figures S4A–S4C). As our previous studies have demonstrated,
negative regulation of primitive erythropoiesis by both Notch
activation and canonical Wnt inhibition (Chen et al., 2008; Cheng
et al., 2008; Nostro et al., 2008), we speculated that coculture
with Vcam-1+ cells could be regulating EryP potential via these
pathways. However, coculture with mESC RBPJk/-derived
cells (Schroeder et al., 2003), which lack a Notch response, ex-
hibited a similar repression in EryP-CFC potential as RBPJk+/-
derived cells (Figure 5C). Similarly, when 50 ng/ml exogenous
Wnt3a was added to cocultures, no rescue of EryP-CFC poten-
tial was observed (Figure 5D).
As these known regulators of the primitive erythroid lineage
were not involved in this repression, we next investigated5–57, July 17, 2012 ª2012 Elsevier Inc. 51
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Figure 5. Nonhematopoietic, Nonendothe-
lial Vcam-1+ Cells Negatively Regulate
EryP-CFCs inaCellNonautonomousManner
(A) Differentiation scheme depicting the coculture
assay used to assess Vcam-1-mediated inhibition
of EryP-CFC development. Vcam-1+ and CD31+
cells were isolated from day 6 EBs and cultured
for 48 hr on gelatin-coated plates. At this stage,
cells from day 4 EBs (source of EryP-CFCs) were
added, and the two populations were cultured for
an additional 48 hr. Following coculture, the pop-
ulations were harvested and assayed for EryP-
CFC potential.
(B) Relative total number of EryP-CFCs generated
following culture of wild-type EB cells on gelatin,
CD31+ or Vcam1+ cells.
(C) Relative total number of EryP-CFCs generated
from RBPJk+/ and RBPJk/ EB cells coculture
as in (B).
(D) Relative total number of EryP-CFCs generated
following culture of wild-type EB cells on Vcam1+
in the presence of either Wnt3a (50 ng/ml) or Dkk1
(300 ng/ml).
(E) Relative total number of EryP-CFCs generated
following culture of wild-type EB cells on gelatin or
rhVCAM-1-coated plasticware. n R 3. (mean ±
SD) Student’s paired t test *p < 0.05, **p < 0.01.
See also Figure S4.
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Primitive Erythropoiesis Is Regulated by miR-126whether Vcam-1 binding to EryP-CFCs is capable of repressing
its potential. For these studies, we performed similar coculture
assays utilizing other cell lines that express Vcam-1 (Figure S4D)
or rhVCAM-1-coated plasticware. In all cases, EryP-CFCs were
reduced byR50% following Vcam-1+ coculture (Figures 5E and
S4E). These observations clearly demonstrate that exposure of
primitive erythroid progenitors to Vcam-1 restricts their develop-
mental potential.
Apoptosis was not significantly affected by either miR-126
expression or rhVCAM-1 coculture (data not shown), indicating
that the decline in EryP-CFCs is not due to cell death. To
determine if interaction with Vcam-1 impacts the rate of matura-
tion of the EryP-CFCs, the cultures were monitored for expres-
sion of ßh1-globin and the surface markers CD71 and Ter119.
With this analysis, the CD71+Ter119 fraction contains EryP-
CFCs that, following differentiation, give rise to more mature
CD71+Ter119+ cells that no longer display clonogenic potential
(Socolovsky et al., 2001). Emergence of the more differentiated
CD71+Ter119+ fraction was strongly inhibited by either miR-
126 overexpression or Vcam-1 silencing (Figure 6A). Conversely,52 Developmental Cell 23, 45–57, July 17, 2012 ª2012 Elsevier Inc.generation of the CD71+Ter119+ popu-
lation was enhanced when the progeni-
tors were exposed to Vcam-1+ mesen-
chymal cells or to recombinant Vcam-1.
ßh1-globin expression was significantly
decreased in EBs following enforced
expression of miR-126, whereas it was
elevated in miR-126/ EBs compared
to the miR-126+/ EBs (Figure 6B).
Together, these results support the inter-
pretation that interaction of EryP-CFCswith Vcam-1 initiates a signaling cascade that accelerates
maturation resulting in a loss of detectable progenitors.
SFK Inhibition Restores Vcam-1-Inhibited EryP-CFC
Potential
As a first step in identifying potential pathways that mediate
the Vcam-1 effect, we treated wild-type EBs with small mole-
cule inhibitors of known effectors of integrin ‘‘outside-in’’
signaling including Src, Fak, Mek, Pi3K, p38, Jak, Jnk, and
Caspase to determine which, if any, impact primitive erythro-
poiesis. Inhibitors were added at day 4 of differentiation, and
the EBs were assayed at day 6 for EryP-CFCs. Both the SFK
inhibitor PP2 and the MEK inhibitor PD0325901 increased
EryP-CFCs in wild-type EBs (Figure 7A). Although a modest
increase in EryP-CFCs was observed with the Fak inhibitor,
its off-target toxicity (data not shown) may have masked its
effect on primitive erythropoiesis. PP2 was able to rescue
EryP-CFC potential in miR-126/ EBs and to increase the
frequency of progenitors to levels found in miR-126+/ EBs.
Inhibition of MEK, in contrast, did not rescue primitive erythroid
AB
0
2
4
6
8
10
12
14
ßh
1 
gl
ob
in
 /
 A
ct
B 
m
R
N
A
*
D0 D2 D4 D5 D6
Days Differentiation
miR126+/- miR126-/-
0
1
2
3
4
5
6
7
*
No Dox Dox
D0 D2 D4 D5 D6
Days Differentiation
ßh
1 
gl
ob
in
 /
 A
ct
B 
m
R
N
A
49 38
0.0713
75 19
0.15.7
83 1.7
0.515
65 27
0.37.6
60 34
0.25.9
84 5.1
0.211
32 64
0.13.9
38 45
0.0918
i-miR-126
+ Dox
CD31
CD106
Gelatin
rhVCAM1+ Dox
i-Vcam-1 shRNA
C
D
7
1
Ter119
Figure 6. Vcam-1 Exposure to EryP-CFC
Causes Maturation
(A) Representative flow cytometric analysis of
CD71 and Ter119 in day 6 EBs or 48 hr coculture.
Cultures with elevated total Vcam-1+ % have
increased Ter119+ cells, indicative of maturation
and loss of CFC potential.
(B) qRT-PCR on miR-126 overexpression (left) or
miR-126/ (right) of ßh1-globin. Lower miR-126
expression (thus higher Vcam-1 expression;
Figures 3A and 3B) EBs exhibit increased ßh1-
globin expression. n = 3. (mean ± SD) Student’s
paired t test *p < 0.05
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Primitive Erythropoiesis Is Regulated by miR-126potential in these cultures (Figure 7B). Treatment with PP2
significantly reduced Vcam-1 expression in day 6 EBs (Fig-
ure S5A), indicating that this may be the reason for the rescue
in EryP-CFC in the miR-126/ EBs. To further investigate this
possibility, we added PP2 to rhVCAM-1/EryP-CFC cultures
as well as to Vcam-1+ mesenchymal/EryP-CFC cocultures.
Under both conditions, the addition of PP2 rescued the
Vcam-1-mediated EryP-CFC repression (Figures 7C and 7D).
The fact that Vcam-1 levels were not impacted by the PP2 in
the coculture (Figure S5B), and that we observed rescue on
rhVCAM-1, suggested that the kinase is signaling in the EryP-
CFC population.
Analyses of total phosphorylated SFK by western blotting re-
vealed a 25% increase in miR-126/ EBs compared to miR-
126+/ EBs. (Figure 7E), indicating increased activation of this
family of kinases in the absence of miR-126. The modest
increase in phosphorylated SFK is not unexpected given the
broad range of family members expressed in the day 6 EBs
(Figure S5C).
DISCUSSION
Primitive erythropoiesis represents a transient hematopoietic
program that functions to generate a synchronous wave of prim-
itive erythroblasts that are essential for efficient oxygen transport
in the embryo. Primitive erythropoiesis is characterized by theDevelopmental Cell 23, 4rapid emergence and disappearance of
primitive erythroid progenitors within the
yolk sac over a 48 hr period in the mouse
embryo (Palis et al., 1999). Although the
precise timing of EryP-CFC development
has been recognized for more than a
decade, the signaling pathways that
regulate this pattern of erythroid develop-
ment and the termination of progenitor
potential remain poorly understood. In
this report, we provide insights into this
aspect of primitive erythropoiesis and
show the duration of EryP-CFC produc-
tion is controlled in part by miR-126.
Moreover, we show that miR-126 exerts
this effect through a pathway that
involves the regulation of Vcam-1, a previ-
ously published target of this microRNA(Harris et al., 2008), in a cell nonautonomous fashion (model,
Figure 7F).
miR-126 has been reported to play a role in hematopoiesis
at other stages of development. In zebrafish, miR-126 controls
megakaryocyte development through the regulation of c-myb
at the stage of the common erythroid/megakaryocyte progenitor
(Grabher et al., 2010). As c-myb is not expressed in the primitive
erythroid lineage (Tober et al., 2008), these observations indicate
that miR-126 can regulate different stages of hematopoiesis
through different pathways. Within the human hematopoietic
system, miR-126 is expressed in CD34+ human cord blood
and mobilized peripheral blood cells (Donahue et al., 2009; Gar-
zon et al., 2006; Gentner et al., 2010; Jin et al., 2008; Shen et al.,
2008), suggesting that it may play a role in regulating early stage
decisions, possibly at the level of the hematopoietic stem cell.
One report has shown that miR-126 is expressed in EBs gener-
ated from human ESCs using a serum-based protocol (Huang
et al., 2011). In contrast to our findings, however, the authors
observed that enforced expression of miR-126 in the whole EB
population resulted in marked inhibition of erythropoiesis.
PTPN9 was identified as a potential target for this effect, and
its enforced expression was able to partially rescue the observed
inhibition of erythroid development. We did not detect any
changes in Ptpn9 expression following manipulation of miR-
126 in mouse ESC-derived cells (Figures S3C and S3D). The
apparent discrepancies between the two studies may be due5–57, July 17, 2012 ª2012 Elsevier Inc. 53
DMSO PP2 PD0325901
0
2
4
6
8
10
12
14
16
18
20
T
o
ta
l 
#
 E
ry
P
-C
F
C
 (
x
1
0
4
)
miR126+/- miR126-/-
*
* *
F
a
k
S
rc
P
i3
k
M
e
k
p
3
8
J
a
k
J
n
k
C
a
s
p
a
s
e
0
0.5
1
1.5
2
2.5
3
R
e
la
ti
v
e
 #
 E
ry
P
-C
F
C
-
*
*
DMSO PP2 PD0325901
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
R
e
la
ti
v
e
 #
 E
ry
P
-C
F
C
CD31
CD106
**
A B
D E
miR-126+/- miR-126-/-
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
R
e
la
ti
v
e
 P
h
o
s
p
h
o
-
 Y
4
1
6
 /
 T
o
ta
l 
S
rc
 **
Vcam-1
miR-126
SFK
maturation
PP2
Mesenchyme
EryP-CFC
F
Flk-1+
DMSO PP2 PD0325901
0
0.5
1
1.5
2
2.5
rhVCAM1 - + +
R
e
la
ti
v
e
 #
 T
o
ta
l 
E
ry
P
-C
F
C
 
*
C
EryP
Figure 7. Src-Family Kinase Inhibition Alleviates Vcam-1-Mediated EryP-CFC Repression
(A) Relative total EryP-CFC potential in day 6 EBs treated with various kinase inhibitors for 48 hr.
(B) Relative EryP-CFC potential in miR-126+/ and miR-126/ day 6 EBs treated with 10 mM PP2 or 1 mM PD0325901 for 48 hr.
(C and D) Relative EryP-CFC potential in 48 hr cocultures on rhVCAM-1 (C) or with CD31+ or Vcam-1+ cells (D).
(E) Quantification of western blotting for total phosphorylated Y416 Src-family kinase in day 6 EBs. nR 3. (mean ± SD) Student’s paired t test *p < 0.05, **p < 0.01.
(F) Model of Vcam-1-mediated EryP-CFC regulation. Flk-1+ cells give rise to endothelial (not shown), mesenchymal and hematopoietic progenitors. Over time, the
Vcam-1-expressing cells initiate a maturation signal in the EryP-CFC, via a SFK, resulting in loss of CFC potential. miR-126 regulates the expression of Vcam-1,
thereby affecting the temporal regulation of the primitive erythroid program.
See also Figure S5.
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Primitive Erythropoiesis Is Regulated by miR-126to differences in the temporal development and regulation
of mouse and human primitive erythropoiesis. Future studies
utilizing miR-126 antagomirs or knockout human ESC lines,
differentiated under serum-free conditions, will likely be required
to resolve these differing observations.
Vcam-1 binds several different integrins, including a4b1 (Vla-4)
(Chan et al., 1992; Elices et al., 1990), which is expressed on
most hematopoietic lineages, including primitive erythroblasts
(Fraser et al., 2007). Earlier studies have shown that interaction
between Vcam-1 expressed on fetal liver macrophages and
Vla-4 expressed by the primitive erythroblasts is required for
their enucleation (Isern et al., 2008; Kingsley et al., 2004;
McGrath et al., 2008). Our findings indicate that Vcam-1 plays
an additional role at an earlier stage of primitive erythroid devel-
opment where it appears to function on a nonhematopoietic
regulatory population, mediating the termination of EryP-CFC54 Developmental Cell 23, 45–57, July 17, 2012 ª2012 Elsevier Inc.development via induction of their maturation (Figure 7F). This
interpretation is supported by the observations the period of
time during which EryP-CFCs are generated is inversely corre-
lated with the size of the Vcam-1+ population (Figure 3) and
that coculture of EB-derived cells with rhVCAM-1 results in
a reduction of EryP-CFCs (Figure 5E).
The complete rescue of Vcam-1-mediated EryP-CFC repres-
sion by Src inhibition strongly suggests that the effect is medi-
ated by activation of a Src family member in the erythroid
progenitors. Previous studies have shown that SFKs participate
in the regulation of definitive erythropoiesis through a variety
of mechanisms, such as regulation of EPOR, EGFR, and integ-
rin signaling (reviewed in Ingley et al., 2004; Richmond et al.,
2005). Lyn kinase, in particular, has been reported to play
a significant role in erythropoiesis, with Lyn/ mice exhibiting
a striking increase in spleen and bone marrow-derived CFU-E
Developmental Cell
Primitive Erythropoiesis Is Regulated by miR-126(Harder et al., 2004). Our findings extend a regulatory role of
SFKs to the primitive erythroid lineage and, specifically, to the
termination of the program. Current studies are aimed at
determining which family member is responsible for mediating
this effect.
The observation that the Flk-1+ hemangioblast population is
able to generate both the Vcam-1+ regulatory cells and the
primitive erythroid lineage suggests that they may be derived
from a common progenitor. While the exact nature of the
Vcam-1+ population remains unknown, our findings to date indi-
cate it represents a mesenchymal population capable of tri-
lineage differentiation. The surface marker phenotype of the
mESC-derived Vcam-1+ MSCs is distinct from those generated
from adult tissues, suggesting they may represent a unique pop-
ulation that functions transiently in the yolk sac, providing a
regulatory niche to trigger erythroid maturation and termination
of progenitor development.
The dynamics of Vcam-1 expression in the developing yolk
sac (Figure 3F) and the presence of a distinct Vcam-1+ popula-
tion in 4-6 sp pair yolk sacs is consistent with a role for this
molecule in regulating primitive erythropoiesis in vivo. EryP-
CFC development in the yolk sac initiates at E7.0 and persists
until E8.5 (Palis et al., 1999). The presence of Vcam-1+ cells in
the yolk sac during late stages of primitive erythropoiesis
supports the interpretation that they function to regulate the
duration of the progenitor development in vivo, as they do
in vitro. The dramatic drop in levels of Vcam-1 expression
over a matter of hours between the 7-9 sp and 10-14 sp stages
of development indicates that the MSC population, or at least
Vcam-1 expression, is tightly controlled at this stage. The sharp
spike in miR-126-3p at this stage supports the interpreta-
tion that its expression is responsible for this rapid decline in
Vcam-1. miR-126-3p is expressed during the primitive erythroid
stage of yolk sac development, at levels that may function to
balance the size of the MSC population or the amount of
Vcam-1 expressed. The observation that miR-126-3p null
embryos have reduced numbers of EryP-CFCs demonstrates
that these levels of expression are functional and important
for regulating primitive erythroid development in vivo. Given
the rapid temporal changes in Vcam-1 expression and limited
access to tissues at this stage of development, observations
of a direct correlation between miR-126-3p and Vcam-1 ex-
pression in the mutant embryos is not possible. The compli-
mentary findings from the mESC model recapitulating primitive
erythropoiesis in vivo highlight the power of this in vitro system
for studying lineage specification and once again demonstrate
that developmental events in vitro accurately recapitulate those
in the early embryo.
In summary, the findings in this study provide evidence of
a pathway that regulates the terminal stages of primitive
erythroid progenitor development in the mESC model as well
as in the mouse embryo yolk sac. The identification of a
Vcam-1+ population that is regulated in part by miR-126
uncovers a cell nonautonomous pathway for controlling primi-
tive erythropoiesis. With access to this regulatory population, it
will be possible to study the mechanisms through which it
mediates this effect and determine if it plays a larger role in the
transition from the primitive to definitive hematopoietic programs
in ESC-derived differentiation cultures.DEXPERIMENTAL PROCEDURES
ESC Maintenance and Differentiation
All mESC lines were maintained and differentiated under feeder-free, serum-
free conditions (Gadue et al., 2006) as described in Supplemental Experi-
mental Procedures.
EryP-CFC Assays
Primitive erythroid progenitor assays were performed as previously described
(Nostro et al., 2008; Palis et al., 1999). Differentiation reaggregates were trypsi-
nized to single-cells and plated in IMDM/methylcellulose containing 10%
plasma-derived serum, 5% PFHM-II, 300 mg/ml transferrin, 2U/ml EPO,
2 mM glutamine, 50 mg/ml ascorbic acid, and 4.5 3 104 M 1-thioglycerol.
Colonies (EryP-CFC) were scored 5 days after plating. Values presented repre-
sent averages across three or more replicates, ± SD. Student’s paired t test
and ANOVA statistical analysis were used to determine significance (p <
0.05) in different colony-forming potential between groups.
Coculture EryP-CFC Assay
Sorted Vcam-1+ cells from day 6 differentiation cultures were plated onto
gelatin-coated 96-well plates at 20,000 cells/well in SFD containing 25 ng/ml
hPDGF-BB and 10 ng/ml hFGF-2. Sorted CD31+ cells from the same cultures
were plated in 50 ng/ml hVEGF and 10 ng/ml hFGF-2. Recombinant human
Vcam-1 (10 mg/ml; BD Biosciences) was coated on 96-well plates for 1 hr prior
to cell seeding. Cells were cultured for 48 hr, then washed in IMDM and over-
layed with 50,000 day 4 EB cells in SFD with 5 ng/ml hVEGF. Cocultures were
harvested (suspension and adherent fractions) 48 hr later and assayed for
EryP-CFC activity.
Kinase Inhibitor EryP-CFC Assays
mESCwere differentiated and assayed as above, but small molecule inhibitors
were added at day 4 of differentiation in place of DOX. FAK inhibitor PF573228
(1 mM), Src inhibitor PP2 (10 mM), PI3K inhibitor LY294002 (20 mM), MEK inhib-
itor PD0325901 (1 mM), p38 inhibitor SB203580 (10 mM), JAK inhibitor AG490
(1 mM) JNK inhibitor SP600125 (10 mM), and caspase inhibitor Z-VAD-FMK
(10 mM) were obtained from Tocris.
In Vivo Analysis
Embryos from timed matings were harvested from E7.0-8.5. Yolk sacs were
dissected and the allantois was removed and then dissociated by trypsiniza-
tion for 5 min. Resultant cells were analyzed by flow cytometry, harvested
for qRT-PCR, or plated in methylcellulose for EryP-CFC analysis. EryP-CFC
values presented represent average ±SEM. ANOVA statistical analysis was
used to determine significance (p < 0.05) in different colony-forming potential
between groups. The embryo proper was used for genotypingmiR-126 status.
Work involving mouse tissue collection and analysis was carried out in accor-
dancewith and approved through the Animal Care Committee at the University
Health Network.
Microarray for MicroRNA
MicroRNA expression was analyzed by microarray as previously described
(Thomson et al., 2004). Briefly, 5 mg total RNAwas labeledwith Cy3 and hybrid-
ized to a custom oligonucleotide microarray. Intensity values were filtered to
remove values below 23 background and the global median center was
normalized. Hierarchical clustering was performed. A clade of the full heat
map is shown in Figure S1B. Microarray data can be accessed at the NCBI
GEO database with accession number GSE37727.
Mesenchymal Lineage Potential Assays
Sorted Vcam-1+ cells were plated onto gelatin-coated 96-well plates at serial
dilutions in SFD. Osteoblastic differentiation was induced using the StemPro
Osteogenesis Differentiation kit (Life Technologies) for 21 days. Adipocyte
differentiation was induced using the Mesenchymal Adipogenesis kit (Milli-
pore) for 21 days. Chondrocyte differentiation was induced by the addition
of 100 mg/ml BMP4 and 10 mg/ml bFGF for 9 days. Cells were fixed in 4%
paraformaldehyde for 20 min at room temperature and then stained with
Alizarin Red (osteogenesis), Oil Red O (adipogenesis), or Alcian Blue
(chondrogenesis).evelopmental Cell 23, 45–57, July 17, 2012 ª2012 Elsevier Inc. 55
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EBs were dissociated to single cells with trypsin and incubated in
IMDM+0.02% BSA (Sigma) with antibodies for the following surface antigens:
anti-mouse VEGFR2-biotin, anti-mouse CD31-PE or -APC, anti-mouse CD41-
FITC or -APC, anti-mouse Vcam-1-biotin, anti-mouse CD73-PE, anti-mouse
CD105-APC, anti-mouse CD90-Pacific Blue, and streptavidin-PE or -APC
(BD). Cells were acquired with an LSR II (BD) or sorted with using a FACSAriaII
(SickKids, UHN Flow Cytometry Facility, Toronto, ON, Canada). Analysis was
performed with FlowJo software (Tree Star, Inc.).
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